Chr. Hansen A/S has reached a settlement with Glycom A/S of several patent disputes, including litigations in Denmark, relating to the production of Human Milk Oligosaccharides (HMOs)
The disputes were inherited by Chr. Hansen through the acquisition of Jennewein Biotechnologie GmbH in 2020.
As part of the settlement of the patent disputes, Chr. Hansen and Glycom have agreed on royalty-bearing patent licenses. The parties have agreed to disclose no further details of the settlement agreement.
The settlement makes it possible for the companies to use their respective technologies to bring the microbiome-beneficial Human Milk Oligosaccharides into more products in the near future to the benefit of consumers.
Chr. Hansen intends to maintain and expand the acquired portfolio of intellectual property rights covering HMOs and the production hereof and will keep enforcing such IP rights.
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable biotech company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.